From Insight to Action: Tackling the MASLD and MASH Epidemic-Module 1: Understanding MASLD and MASH in Endocrinology

Video Transcription

Video Summary

Dr. Rajpal’s webinar on MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction Associated Steatohepatitis) highlights the rising global prevalence and severe health consequences of these liver conditions, especially in patients with type 2 diabetes, obesity, PCOS, and hypercortisolism. MASLD, formerly NAFLD, reflects metabolic dysfunction rather than alcohol use. The disease progresses from hepatic steatosis to inflammation, fibrosis, cirrhosis, and possibly liver cancer, with fibrosis stage strongly predicting mortality. Insulin resistance plays a central role, promoting liver fat deposition and inflammation. Patients with type 2 diabetes have notably higher MASLD prevalence and risk of advanced fibrosis. MASLD also increases cardiovascular risks. Endocrinologists should screen high-risk patients, including those with PCOS and glucocorticoid excess, for MASLD early to prevent progression. Early identification and management of MASLD should be integrated into endocrine practice to improve liver health and reduce morbidity and mortality among these vulnerable populations.

Meta Tag

Concept Steatotic Liver Disease

Concept Fatty Liver Disease

Concept Metabolic Dysfunction-Associated Steatohepatitis

Concept Insulin Resistance

Concept Hepatic Steatosis

Concept Fibrosis

Concept Type 2 Diabetes

Concept Obesity

Concept Fibrosis Risk Stratification

Keywords

MASLD

MASH

type 2 diabetes

obesity

insulin resistance

liver fibrosis

Steatotic Liver Disease

Fatty Liver Disease

Metabolic Dysfunction-Associated Steatohepatitis

Insulin Resistance

Hepatic Steatosis

Fibrosis

Type 2 Diabetes

Obesity

Fibrosis Risk Stratification